TGF beta signaling pathway

Shattuck Labs Presents Preclinical Data at the 2022 American Association for Cancer Research (AACR) Annual Meeting

Retrieved on: 
Friday, April 8, 2022
Cytokine, FC, CD20, NASDAQ, Lymphoma, CD47, Mouse, AACR, Poster, American Association, TGF beta signaling pathway, Cancer, PD-1, Autoimmune disease, ARC, TNF, Association, HVEM, TIGIT, PVR, CD19, GLOBE, Myelocyte, Primate, BTN3A1, Patient, Vaccine, Medical imaging, CD40

AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting. This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the company’s ARC® platform, and the company’s GADLEN platform.

Key Points: 
  • AUSTIN, TX and DURHAM, NC, April 08, 2022 (GLOBE NEWSWIRE) -- Shattuck Labs, Inc. (Shattuck) (NASDAQ: STTK), a clinical-stage biotechnology company pioneering the development of bi-functional fusion proteins as a new class of biologic medicine for the treatment of patients with cancer and autoimmune disease, today announced preclinical data at the 2022 American Association for Cancer Research (AACR) Annual Meeting.
  • This includes data from SL-9258 (TIGIT-Fc-LIGHT), derived from the companys ARC platform, and the companys GADLEN platform.
  • We have made excellent progress advancing compounds in our preclinical pipeline, said Taylor Schreiber, M.D., Ph.D., Chief Executive Officer of Shattuck.
  • Together, these results suggest that TIGIT-Fc-LIGHT may provide clinical benefit to patients that are refractory to conventional checkpoint blockade therapy.

2021 Report on TGF Beta Receptor Type 2 Drugs in Development - Featuring Auxagen, InteRNA Technologies and Velvio Among Others - ResearchAndMarkets.com

Retrieved on: 
Tuesday, June 22, 2021
Health, Pharmaceutical, Branches of biology, Proteins, Biology, TGF beta receptors, Signal transduction, TGF beta receptor 2, Growth factors, Transforming growth factor beta, Transforming growth factor, TGF beta signaling pathway, TGF beta receptor 1

The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Drugs in Development, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to this report TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) pipeline Target constitutes close to 7 molecules.
  • TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) - Transforming growth factor beta receptor II is a TGF beta receptor encoded by TGFBR2 gene.
  • It also reviews key players involved in TGF Beta Receptor Type 2 (Transforming Growth Factor Beta Receptor Type II or TGFBR2 or EC 2.7.11.30) targeted therapeutics development with respective active and dormant or discontinued projects.

Advances in Transforming Growth Factor-β Signaling

Retrieved on: 
Wednesday, February 17, 2021
Branches of biology, Proteins, Protein structure, Signal transduction, Transforming growth factor beta, TGF beta receptors, Transforming growth factor, Cytokine, Activin and inhibin, TGF beta Activation, TGF beta signaling pathway

Transforming growth factor beta (TGF-) is a multifunctional cytokine produced in all white blood cells lineages.

Key Points: 
  • Transforming growth factor beta (TGF-) is a multifunctional cytokine produced in all white blood cells lineages.
  • Thompson said "This study helps bring into focus how antagonists of the TGF-family are positioned on the cell surface and how this could potentially impact signaling.
  • The binding of follistatin and heparin unexpectedly impaired the association of mysostatin and activin A which are ligands of the TGF-family.
  • Experimental Biology and Medicine is a global journal dedicated to the publication of multidisciplinary and interdisciplinary research in the biomedical sciences.